Is MapLight Therapeutics, Inc. a good investment? MapLight Therapeutics, Inc. (MPLT) is currently trading at 7.25 USD. Market analysts have a consensus price target of 26.54 USD. This suggests a potential upside from current levels.
Earnings Schedule: MapLight Therapeutics, Inc. is expected to release its next earnings report on Dec. 3, 2026. The market consensus estimate for Forward EPS is -3.42.
No, it does not currently pay a dividend.
MapLight Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Dec. 3, 2026. The company currently has a trailing EPS of -6.25.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Community Discussion